Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents

NCT05030675 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Refractory Chronic Myelomonocytic Leukemia
Refractory Myelodysplastic Syndrome

Interventions

DRUG: Fostamatinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]